Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov062019	Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting FT596 Selected by ASH for Feature at “CAR-T and Beyond” P ress Conference on December 7 Two Oral and Four Poster Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event at ASH on December 6 SAN DIEGO , Nov. Read All »	View HTML
Toggle SummaryNov142019	Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference SAN DIEGO , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All »	View HTML
Toggle SummaryNov272019	Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference SAN DIEGO , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Ph.D., Chief Scientific Officer, Read All »	View HTML
Toggle SummaryDec072019	Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or FT500-related SAEs Reported in First 12 Patients Treated with FT500 for Advanced Solid Tumors Favorable Read All »	View HTML
Toggle SummaryDec082019	Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma Combination of FT596 with Rituximab Shows Durable Tumor Clearance In Vivo in Preclinical Lymphoma Model Company Plans to Initiate Enrollment of First-in-human Clinical Read All »	View HTML
Toggle SummaryDec102019	Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus with No Evidence of Off-target Effects Read All »	View HTML
Toggle SummaryJan132020	Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood FT516 IND Application Cleared by FDA for Advanced Solid Tumors in Combination with PDL1-, EGFR- and HER2-targeting Therapeutic Antibodies Published Preclinical Data Demonstrate iPSC-derived NK Cells Engineered with High-affinity, Non-cleavable CD16 Enhance the Efficacy of Antibody Therapy SAN DIEGO Read All »	View HTML
Toggle SummaryFeb072020	Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today its participation in the following upcoming investor Read All »	View HTML
Toggle SummaryFeb262020	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results SAN DIEGO , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryMar022020	Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook Reported Initial Clinical Data from FT500 Phase 1 Study in Advanced Solid Tumors, Supporting Safety and Tolerability of Multi-dose Treatment Paradigm for Off-the-shelf, iPSC-derived NK Cells First Patients Treated with FT516, the First-ever Engineered iPSC-derived Cellular Immunotherapy, for AML Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.